| Literature DB >> 27738647 |
Fabienne Harrisberger1, Roman Buechler2, Renata Smieskova3, Claudia Lenz1, Anna Walter1, Laura Egloff1, Kerstin Bendfeldt4, Andor E Simon5, Diana Wotruba2, Anastasia Theodoridou2, Wulf Rössler2, Anita Riecher-Rössler1, Undine E Lang1, Karsten Heekeren2, Stefan Borgwardt6.
Abstract
Reduction in hippocampal volume is a hallmark of schizophrenia and already present in the clinical high-risk state. Nevertheless, other subcortical structures, such as the thalamus, amygdala and pallidum can differentiate schizophrenia patients from controls. We studied the role of hippocampal and subcortical structures in clinical high-risk individuals from two cohorts. High-resolution T1-weighted structural MRI brain scans of a total of 91 clinical high-risk individuals and 64 healthy controls were collected in two centers. The bilateral volume of the hippocampus, the thalamus, the caudate, the putamen, the pallidum, the amygdala, and the accumbens were automatically segmented using FSL-FIRST. A linear mixed-effects model and a prospective meta-analysis were applied to assess group-related volumetric differences. We report reduced hippocampal and thalamic volumes in clinical high-risk individuals compared to healthy controls. No volumetric alterations were detected for the caudate, the putamen, the pallidum, the amygdala, or the accumbens. Moreover, we found comparable medium effect sizes for group-related comparison of the thalamus in the two analytical methods. These findings underline the relevance of specific alterations in the hippocampal and subcortical volumes in the high-risk state. Further analyses may allow hippocampal and thalamic volumes to be used as biomarkers to predict psychosis.Entities:
Year: 2016 PMID: 27738647 PMCID: PMC5040554 DOI: 10.1038/npjschz.2016.33
Source DB: PubMed Journal: NPJ Schizophr ISSN: 2334-265X
Demographics and clinical characteristics for the linear mixed-effects model
| Gender M/F (%male) | 29/16 (64%) | 21/22 (49%) | ||
| Mean age in years (s.d.) | 23.55 (5.28) | 26.16 (4.74) | ||
| Handedness r/l (%left) | 41/4 (9%) | 39/3 (7%) | ||
| Years of education (s.d.) | 12.27 (2.92) | 15.31 (2.91) | ||
| IQ (s.d.) | 108 (15.58) | 115 (14.43) | ||
| Negative cluster (s.d.) | 6.86 (2.86) | 3.00 (0) | ||
| Positive cluster (s.d.) | 9.07 (3.19) | 4.00 (0) | ||
| GAF (s.d.) | 58.20 (11.80) | 88.17 (4.22) | ||
| Scanner ZH1/ZH2/BS | 8/11/26 | 5/14/24 | ||
| Antidepressants no/yes | 30/15 | 43/0 |
Abbreviations: F, female; GAF, global functioning; IQ, intelligent quotient; l, left; M, male; r, right; *, significant findings.
Positive symptom cluster=either sum of Suspiciousness, Hallucinations, Unusual Thought Content and Conceptual Disorganisation (BPRS9, BPRS10, BPRS11, BPRS15 in Basel and PANSS P2, PANSS P3, PANSS P6, PANSS G9 in Zurich).
Negative symptom cluster=either sum of Blunted Affect, Emotional Withdrawal and Motor Retardation (BPRS16, BPRS17, BPRS18 in Basel and PANSS N1, PANSS N2, PANSS G7 in Zurich).
Demographics and clinical characteristics for the prospective meta-analysis
| Gender M/F (%male) | 59/32 (64%) | 33/31 (52%) | ||
| Mean age in years (s.d.) | 23.70 (5.11) | 25.50 (4.76) | ||
| Handedness r/l (%left) | 84/7 (8%) | 57/7 (11%) | ||
| Years of education (s.d.) | 12.90 (3.00) | 14.89 (2.97) | ||
| IQ (s.d.) | 108 (15.31) | 112 (14.38) | ||
| Negative cluster (s.d.) | 6.54 (3.17) | 3.00 (0) | ||
| Positive cluster (s.d.) | 9.02 (3.52) | 4.00 (0) | ||
| GAF (s.d.) | 61.05 (14.83) | 88.08 (4.15) | ||
| Scanner ZH1/ZH2/BS | 16/15/60 | 5/35/24 | ||
| Antidepressants no/yes | 59/32 | 64/0 | ||
| Antipsychotics no/yes | 84/7 | 64/0 |
Abbreviations: F, female; GAF, global functioning; IQ, intelligent quotient; l, left; M, male; r, right; *, significant findings.
Positive symptom cluster=either sum of Suspiciousness, Hallucinations, Unusual Thought Content and Conceptual Disorganisation (BPRS9, BPRS10, BPRS11, BPRS15 in Basel and PANSS P2, PANSS P3, PANSS P6, PANSS G9 in Zurich).
Negative symptom cluster=either sum of Blunted Affect, Emotional Withdrawal and Motor Retardation (BPRS16, BPRS17, BPRS18 in Basel and PANSS N1, PANSS N2, PANSS G7 in Zurich).
Results of linear mixed-model analysis
| P | P | P | P | P | P | P | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis (1, 82) | 16.91 | <0.001* | 10.22 | 0.002* | 4.48 | 0.04* | 3.04 | 0.09 | 3.84 | 0.05 | 1.67 | 0.20 | 6.10 | 0.02* |
| Hemisphere (1, 82) | 0.01 | 0.93 | 0.19 | 0.67 | 0.32 | 0.58 | 0.36 | 0.55 | 0.31 | 0.58 | 0.15 | 0.70 | 0.85 | 0.36 |
| Site (2, 82) | 0.97 | 0.38 | 1.36 | 0.26 | 2.33 | 0.10 | 0.44 | 0.65 | 0.23 | 0.79 | 0.60 | 0.55 | 0.05 | 0.95 |
| Diagnosis×hemisphere (1, 82) | 0.32 | 0.57 | 0.01 | 0.94 | 0.0003 | 0.99 | 0.04 | 0.84 | 0.59 | 0.44 | 0.51 | 0.48 | 4.95 | 0.03* |
| Diagnosis×site (2, 82) | 3.09 | 0.05 | 0.12 | 0.89 | 1.95 | 0.15 | 3.09 | 0.05 | 0.52 | 0.59 | 4.21 | 0.02* | 1.07 | 0.35 |
| Diagnosis×site×hemisphere (4, 82) | 1.19 | 0.32 | 0.57 | 0.69 | 2.23 | 0.07 | 1.70 | 0.16 | 1.89 | 0.12 | 0.32 | 0.87 | 0.84 | 0.51 |
| Sex (1, 82) | 18.93 | <0.001* | 0.04 | 0.84 | 1.78 | 0.19 | 0.62 | 0.43 | 0.08 | 0.78 | 3.42 | 0.07 | 0.00 | 0.98 |
| Age (1, 82) | 0.09 | 0.76 | 0.01 | 0.92 | 10.03 | 0.002* | 1.97 | 0.16 | 0.27 | 0.60 | 1.79 | 0.19 | 2.22 | 0.14 |
| Education (1, 82) | 4.59 | 0.04* | 1.47 | 0.23 | 0.02 | 0.89 | 0.02 | 0.88 | 0.26 | 0.61 | 1.13 | 0.29 | 0.05 | 0.82 |
Abbreviations: dd.f., denominator degrees of freedom; corrected for multiple comparison; nd.f., nominator degrees of freedom; *, significant findings.
Figure 1Forest plot of prospective, random effects meta-analyses investigating the difference between: (a) hippocampal volumes and group affiliation. (b) Thalamic volumes and group affiliation. Negative values represent smaller volumes for CHR than in HC. The dashed line is the zero line of no difference between groups.
Effect sizes of group-related comparison with bilateral, left and right volume of each stucture
| BS | −0.38 | 0.24 | −0.21 | 0.24 | −0.39 | 0.24 |
| ZH1 | −0.36 | 0.52 | −0.14 | 0.51 | −0.47 | 0.52 |
| ZH2 | −0.38 | 0.31 | −0.52 | 0.31 | −0.13 | 0.31 |
| BS | −0.61 | 0.25 | −0.52 | 0.24 | −0.64 | 0.25 |
| ZH1 | −0.57 | 0.52 | −0.26 | 0.51 | −0.73 | 0.52 |
| ZH2 | −0.60 | 0.31 | −0.69 | 0.32 | −0.45 | 0.31 |
| BS | 0.17 | 0.24 | 0.18 | 0.24 | 0.14 | 0.24 |
| ZH1 | −0.40 | 0.52 | −0.26 | 0.51 | −0.50 | 0.52 |
| ZH2 | −0.12 | 0.31 | −0.34 | 0.31 | 0.11 | 0.31 |
| BS | 0.22 | 0.24 | 0.18 | 0.24 | 0.25 | 0.24 |
| ZH1 | 0.17 | 0.51 | 0.28 | 0.51 | 0.04 | 0.51 |
| ZH2 | −0.38 | 0.31 | −0.58 | 0.31 | −0.14 | 0.31 |
| BS | −0.05 | 0.24 | 0.04 | 0.24 | −0.13 | 0.24 |
| ZH1 | 0.04 | 0.51 | −0.13 | 0.51 | 0.19 | 0.51 |
| ZH2 | −0.16 | 0.31 | −0.07 | 0.31 | −0.20 | 0.31 |
| BS | 0.21 | 0.24 | 0.17 | 0.24 | 0.17 | 0.24 |
| ZH1 | −0.28 | 0.51 | −0.01 | 0.51 | −0.40 | 0.52 |
| ZH2 | −0.35 | 0.31 | −0.30 | 0.31 | −0.29 | 0.31 |
| BS | −0.02 | 0.24 | 0.10 | 0.24 | −0.13 | 0.24 |
| ZH1 | −0.56 | 0.52 | −0.29 | 0.51 | −0.58 | 0.52 |
| ZH2 | −0.14 | 0.31 | 0.04 | 0.31 | −0.28 | 0.31 |
Abbreviations: BS, Basel; ZH, Zürich.
BS and ZH negative effect sizes represent smaller volumes for clinical high-risk individuals than healthy controls. Positive effect sizes represent larger volumes for clinical high-risk individuals than healthy controls.